---
title: "Telix Pharmaceuticals Limited (TLX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TLX.US.md"
symbol: "TLX.US"
name: "Telix Pharmaceuticals Limited"
industry: "Biotechnology"
datetime: "2026-05-20T02:19:06.944Z"
locales:
  - [en](https://longbridge.com/en/quote/TLX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TLX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TLX.US.md)
---

# Telix Pharmaceuticals Limited (TLX.US)

## Company Overview

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [elixpharma.com](https://elixpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: B (0.39)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 28 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 55.61% |  |
| Net Profit YoY | -121.15% |  |
| P/B Ratio | 8.38 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3482628063.72 |  |
| Revenue | 803794000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1.85% | D |
| Profit Margin | -0.89% | D |
| Gross Margin | 47.51% | B |
| Revenue YoY | 55.61% | A |
| Net Profit YoY | -121.15% | E |
| Total Assets YoY | 23.78% | A |
| Net Assets YoY | 17.69% | A |
| Cash Flow Margin | 242.71% | A |
| OCF YoY | 55.61% | A |
| Turnover | 0.76 | B |
| Gearing Ratio | 64.31% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Telix Pharmaceuticals Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "55.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-121.15%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.38",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3482628063.72",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "803794000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1.85%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.89%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "47.51%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "55.61%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-121.15%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "23.78%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "17.69%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "242.71%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "55.61%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.76",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "64.31%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -483.56 | 549/386 | 309.83 | 239.21 | 168.78 |
| PB | 8.29 | 382/386 | 12.92 | 8.05 | 6.30 |
| PS (TTM) | 4.29 | 94/386 | 8.86 | 4.80 | 3.83 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.17 |
| Highest Target | 22.88 |
| Lowest Target | 20.13 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TLX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TLX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TLX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TLX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**